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Background and purpose: The penile bulb (PB) dose may be critical in development of post prostate radio-
therapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-
volume histograms (DVHs) in patients treated with prostate radiotherapy, and to identify clinical and
dosimetric parameters that predict the risk of ED post prostate radiotherapy.
Materials and methods: Penile bulb DVHs were generated for 276 patients treated within the randomised
IGRT substudy of the multicentre randomised trial, CHHiP. Incidence of ED in relation to dose and ran-
domised IGRT groups were evaluated using Wilcoxon rank sum, Chi-squared test and atlases of compli-
cation incidence. Youden index was used to find dose-volume constraints that discriminated for ED.
Multivariate analysis (MVA) of effect of dosimetry, clinical and patient-related variables was performed.
Results: Reduced treatment margins using IGRT (IGRT-R) produced significantly reduced mean PB dose
compared with standard margins (IGRT-S) (median: 25 Gy (IGRT-S) versus 11 Gy (IGRT-R);
p < 0.0001). Significant difference in both mean (median: 23 Gy (ED) vs. 18 Gy (no ED); p = 0.011) and
maximum (median: 59 Gy (ED) vs. 52 Gy (no ED); p = 0.018) PB doses between those with and without
clinician reported ED were identified. Mean PB dose cut-point for ED was derived at around 20 Gy. On
MVA, PB mean dose and age predicted for impotence.
Conclusion: PB dose appears predictive of post-radiotherapy ED with calculated threshold mean dose of
around 20 Gy, substantially lower than published recommendations. IGRT-R enables favourable PB
dosimetry and can be recommended provided prostate coverage is not compromised.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The current management options for localised prostate cancer
enable excellent local tumour control with long term survival [1].
However, prostate cancer and its treatment are the leading cause
of cancer years lived with a disability [2]. Evaluating treatment
related toxicities are essential to inform patient decisions. There
are limited data on the association of erectile dysfunction (ED) to
external beam radiotherapy for prostate cancer, despite ED being
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and psychosocial health and may profoundly impact the quality
of life of patients and their partners [4–6].
Pelvic radiation-induced complications have been shown to be
dose and volume dependent and have been extensively explored
for bowel and urinary toxicity [7]. For ED post-radiotherapy there
are uncertainties surrounding the most relevant normal tissues
and the multifactorial causes of ED other than those attributable
to the treatment. The penile bulb (PB) has attracted most interest
as a critical normal tissue structure.
Treatment planning dose objectives for the PB have been varied
and inconsistent within the literature [8] and developed from data
using older prostate radiotherapy techniques and dose fractiona-
tion schedules. More recently, prostate cancer has been found to
have radiobiological features atypical of most other cancers and
hypofractionation has been hypothesised as a method to improve
the therapeutic ratio [9–11]. In the largest randomised trial world-
wide comparing conventional and hypofractionated prostate
radiotherapy (CHHiP), the long term side effects were similar with
2 Gy and 3 Gy fractionation schedules [9]. Recommended PB dose
constraints for hypofractionated schedules are not established [12]
and those for standard fractionations within the QUANTEC papers
need to be substantiated using data from patients treated with
modern radiotherapy techniques [3].
The primary aim of this study was to determine whether rela-
tionships exist between reduced target volume margins, PB dose
and ED as assessed by clinician reported outcomes using both con-
ventional and hypofractionated radiotherapy. The secondary aims
were to derive radiotherapy dose constraints that could be imple-
mented into radiotherapy planning to potentially decrease inci-
dence of ED. Additionally, multivariate analysis (MVA) was
performed to identify clinical and dosimetric parameters that pre-
dict risk of ED in patients treated with prostate image guided
radiotherapy (IGRT).2. Materials and methods
The CHHiP (Conventional or Hypofractionated High-dose Inten-
sity Modulated Radiotherapy in Prostate Cancer; CRUK/06/016)
study is a multicentre randomised controlled trial which used a
three-arm design comparing conventionally fractionated radio-
therapy (74 Gy in 37 2 Gy fractions (f)) with high-quality radiation
techniques delivered using two different 3 Gy hypofractionated
radiotherapy dose schedules (60 Gy in 20f and 57 Gy in 19f) [9].
A multicentre randomised non-blinded IGRT substudy received
approval by Central London REC1 Research Ethics Committee (10/
H0718/31) on 25th June 2010 and was implemented within the
main CHHiP trial protocol (v 9.0). This substudy assessed acute
and late toxicity associated with daily online IGRT and the feasibil-
ity of daily online IGRT delivery in a national trial. In the main
CHHiP trial patients were randomised 1:1:1 to the fractionation
schedules. Patients consenting to the IGRT substudy were also ran-
domly allocated by minimisation, to (a) no daily online IGRT (i.e.
centre standard verification methods) – using standard treatment
planning margins, (b) daily online IGRT using standard treatment
planning margins (IGRT-S), or (c) daily online IGRT with reduced
treatment planning margins (IGRT-R). Centres had the option to
randomise among all 3 options or alternatively a versus b or b ver-
sus c to accommodate existing centre experience using IGRT
(Figs. E1, E2). The radiotherapy planning techniques have been pre-
viously described [13,14]. Target volume dose coverage was
achieved using a simultaneous integrated boost technique with
mandatory and optimal normal tissue dose constraints (Table E1).
The IGRT substudy commenced after the main CHHiP patient
reported outcome (PRO) study had closed, an additional cross-sectional questionnaire study was approved by ethics (14/
SW/1071) in September 2014.
2.1. Data collection
Patient demographic data was collected at trial entry. Clinician
reported (CRO) ED, measured using Royal Marsden Hospital (RMH)
erectile potency (EP) grading system, was prospectively recorded
at baseline, pre-radiotherapy and at 6 monthly intervals up until
2 years post-radiotherapy and thereafter annually. Grade 0 repre-
sented normal erection, grade 1 decreased erectile potency and
grade 2 absent erectile function. Clinician reported Grade 2 EP
was used as a toxicity endpoint, and patients were excluded from
the analysis if baseline scores were reported as Grade 2. In the PRO
substudy, data was collected at a single time point (at least 3 years
from completing treatment) and included the use of the Expanded
Prostate Cancer Index Composite (EPIC) questionnaire (EPIC-26 for
sexual and hormonal domains) [15]. A cut-point of 33 for EPIC-26
sexual summary group score [16] was used as an endpoint.
Dosimetry information, including full treatment planning data,
was uploaded to a dedicated software platform, VODCA (MSS Inc,
Hagendorn, Switzerland).
2.2. Penile bulb dosimetric analysis
PB was contoured retrospectively by one clinical oncologist (JM)
(Fig. E3) combining RTOG consensus panel atlas for pelvic normal
tissue contouring guidelines [17], well-established anatomic
boundaries [18] and DUE-01 study guidelines [19]. The lateral bor-
ders of the PB included the paired crura, anteriorly the corpus
spongiosum and posteriorly the levator ani. The PB was outlined
posterior to the urethra, with a round shape. The anterior border
of the PB contour in the most cranial slice was used to guide the
anterior border on the more caudal slices. Three-dimensional
physical dose distributions were converted into equivalent dose
in 2 Gy/f (EQD2) distributions by applying Withers formula [20]
with a/b = 3 Gy [12,21] to each dose grid voxel. EQD2-based and
physical dose-based PB dose-volume histogram data were
exported from the analysis software.
Dosimetric atlases of complication incidence (ACI) [22] were
created using Matlab version R2016a (Mathworks, Natick, MA).
ACI are a method of summarising toxicity and cumulative dose-
volume data for an organ of interest, displayed as a dose-volume
grid. Each box within the atlas describes a small range of dose
and volume (5 Gy and 10%, respectively) and presents a numeric
fraction (i.e. denominator = patients whose DVH falls within the
range of dose and volume of the box; numerator = number of
patients whose DVH falls within the range of dose and volume of
the box and who experienced grade 2 EP). PB mean, maximum
dose and volume of PB receiving at least a defined dose were
summarised.
2.3. Statistical methods
PB dosimetry data were compared between patients with or
without the toxicity endpoint using Wilcoxon rank sum with con-
tinuity correction. Exploratory analysis compared ED between the
randomised groups using Chi-squared test of independence. Dose-
volume constraints were derived using receiver operating charac-
teristic (ROC) analysis for individual dose levels (EQD2 and physi-
cal dose) combined with toxicity data. The ‘Youden index’, J [23]
was used to find the volume threshold for each dose level and
the mean and maximum threshold doses that best discriminated
between patients with or without toxicity. A dose metric was con-
sidered to be significantly better than chance at discriminating
between patients with and without toxicity if the lower 95%
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greater than 0.5. The incidence of toxicity in patients who met
the derived constraints was compared with patients who failed
the constraints.
A correlation matrix was produced to check for high correla-
tions between potential prognostic factors, in particular DVH
parameters. Variables with Pearson correlation coefficients 0.80
were combined into a single variable (mean dose) to avoid the
problem of multicollinearity, which may negatively affect general-
isability of the model. PB mean and maximum dose and clinical
variables listed in Table E8 were included in logistic regression
models to predict RMH Grade 2 EP. To develop the prediction
model, univariate logistic regression analysis assessed crude effect
of each candidate variable on the defined endpoint of RMH Grade 2
EP at 2 years. 1000 bootstraps were used for each analysis. Multi-
variable prediction models used the variables significant from uni-
variate analysis. Normal tissue complication probability (NTCP)
model was developed using multivariate logistic regression (R
Development Core Team, R: A language and Environment for sta-
tistical computing, Version 3.3.1). Models were fitted using the
packages glm [24] and leaps with 1000 bootstrap samples of equal
size drawn at random with replacement. Models were fitted using
logistic regression of the form Probability = eA(x)/1 + eA(x) where A
(x) = b0 +
Px¼n
x¼1bnxn, xn are the variables included in the model
and bn are the associated regression coefficients. The final models
to predict RMH Grade 2 EP were assessed using the area under the
ROC (AUC) and the goodness-of-fit of the chosen NTCP model was
evaluated by the Hosmer-Lemeshow test [25]. The chosen NTCP
model for RMH Grade 2 EP was externally validated using a ran-
dom patient cohort from the main CHHiP trial where the PB had
been outlined by a single clinician (AW) using the same PB con-
touring guidelines.3. Results
Baseline characteristics of the 276 patients analysed are
detailed in Table 1 and available data summarised in Fig. 1. PB vol-
ume was similar (p = 0.71) across randomised groups: median
(IQR) was 6.3 (4.8–7.6) cm3 in the no IGRT group, 6.0 (4.9–7.8)
cm3 in the IGRT-S group and 6.1 (4.8–7.6) cm3 in the IGRT-R group.
There were significant PB dose differences between patients trea-
ted with IGRT-S and IGRT-R for both mean and maximum PB dose
(p < 0.0001). Median values of mean (EQD2, alpha/beta 3 Gy) PB
doses were 35 Gy, 25.3 Gy and 10.8 Gy and of maximum doses
68.1 Gy, 61.1 Gy and 36.9 Gy for no IGRT, IGRT-S and IGRT-R
respectively (Fig. 2).3.1. Erectile potency
43/276 (16%) patients were excluded due to RMH Grade 2 EP at
baseline. Of the remaining 233 patients, 191 patients reported year
2 RMH EP score. RMH Grade 2 EP at 2 years after radiotherapy was
reported in 81/191 (42%) patients. 11/33 patients (33%) treated
with no-IGRT had clinician reported ED compared to 37/78 (47%)
in the IGRT-S and 33/80 (41%) in the IGRT-R groups (not signifi-
cantly different, p = 0.37). The median (IQR) testosterone level at
12 months post randomisation in patients with Grade 2 EP was
9.9 (5.9–13.7)nmol/l compared with 12.2 (7.9–14.6)nmol/l in those
reporting Grade 0/1 EP. Patient and clinical factors are grouped
according to 2 year RMH EP score (Table E2). At 4 years, there were
70/163 (43%) patients with RMH Grade 2 EP, 31/66 (47%) were
IGRT-S and 28/72 (39%) IGRT-R patients. Of those with Grade 2
EP at 2 years, 40/81 reported Grade 2 EP, 15/81 Grade 0 or 1 EP
and the status unknown for 26 patients at 4 years. There were
146 patients where the RMH EP status at year 2 and year 4 wererecorded. Of these 45/146 (31%) patients had Grade 0 EP at 2 years,
with 24/45 (53%) patients retaining Grade 0 EP at 4 years, 17/45
(38%) reporting Grade 1 EP and 4/45 (9%) Grade 2 EP at this
timepoint.3.2. Relationship of PB dose to erectile function
Mean and maximum PB doses were significantly lower in
patients with less severe ED post-radiotherapy. In patients with
Grade 2 EP, their median (IQR) mean and maximum PB doses were
23 Gy (8–40 Gy) and 59 Gy (32–69 Gy) and in those patients with
Grade 0/1 EP, it was 18 Gy (8–32 Gy) and 52 Gy (30–66 Gy) respec-
tively (Fig. 3). ACI demonstrate the impact of PB dose and volume
on erectile potency and shows a greater incidence of impotence at
2 years in patients whose DVH fell within the top right of the atlas
compared to those within the bottom left, suggesting a PB dose-
volume response (Fig. 4). This association was also seen at year 3
and 4 endpoints (Fig. E4). The dose volume histogram profiles dis-
tinguishing between those patients with and without RMH Grade 2
EP at 2 years show the association of Grade 2 EP with higher PB
volumes receiving higher doses (Fig. E5). Mean and maximum
doses were 27.4 (11.1–38.7)Gy and 61.8 (42.6–69.0)Gy for patients
with an EPIC-26 sexual summary group score  33 and 14.0 (6.8–
21.8)Gy and 43.0 (20.5–63.5)Gy for patients with EPIC-26 sexual
summary group score > 33 (p = 0.001; Table E3). Median PB DVH
according to EPIC-26 sexual domain average standardised scores
and ACI (Figs. E6/E7) further support a PB dose-volume response.3.3. Derivation of dose constraints
Dose-volume constraints for ED using RMH scoring system over
the range of 10–70 Gy were derived (Table E4). The dose con-
straints (EQD2, alpha/beta 3 Gy) derived for PB mean dose for
CRO (RMH) severe ED was 20 Gy (AUC (95%CI): 0.61(0.53–0.70)).
The derived constraint for maximum PB dose was 56 Gy (AUC
(95%CI): 0.60(0.52–0.69)) for CRO (RMH). Patients who met these
mean and maximum dose constraints were less likely to have
RMH Grade 2 EP (OR: 0.38; 95%CI, 0.21–0.71 and 0.44; 95%CI,
0.24–0.82 respectively; Table E5). Similar derived PB mean dose
constraints were seen for PRO (EPIC-26 sexual domain) severe ED
of 22 Gy (AUC (95% CI): 0.66(0.57–0.74)) and maximum PB dose
of 55 Gy (AUC (95% CI): 0.57(0.65–0.74)); Table E6.
Dose-volume constraints were also derived using physical dose
and RMH EP scoring system. Analysis from patients whose pre-
scription dose was 74 Gy had a statistically significant derived
mean dose constraint of 24 Gy in 37 fractions (AUC (95% CI):
0.71(0.58–0.86), p = 0.002). There was no statistically significant
constraint using physical dose for patients prescribed 3 Gy per
fraction (Table E7).3.4. Development of NTCP model
Univariate analysis demonstrated an association between age,
diabetes, NCCN risk group and PB (EQD2, alpha/beta 3 Gy) mean
dose and impotence using the RMH EP grading scale (Table E8).
Multivariate logistic regression analysis including these variables
showed a relationship between PB mean dose and age (AUC (95%
CI): 0.70(0.62–0.76)); (Fig. 5). External validation of this model
for ED using the RMH EP scale was performed using data from a
random cohort of 232 patients treated within the main CHHiP trial
(Table E9). 48 patients were not included as they had Grade 2 RMH
EP at baseline, therefore 184 patients were evaluated in the NTCP
model. The calculated AUC (95%CI) was 0.68(0.60–0.76); Fig. E8.
Table 1
Baseline demographics, clinical characteristics, and treatment details by randomised group.
No IGRT
N = 46
n (%)
IGRT – S
N = 129
n (%)
IGRT – R
N = 101
n (%)
Main CHHiP trial
N = 3216
n (%)
Age at registration (years)
Median (IQR) 70 (66–73) 72 (66–75) 71 (67–75) 69 (44–85)
T stage (clinical assessment)
T1 14 (30) 41 (32) 40 (40) 1170 (36)
T2 27 (59) 80 (62) 54 (53) 1766 (55)
T3 5 (11) 8 (6) 7 (7) 277 (9)
PSA (pre-hormone treatment) (ng/ml)
Median (IQR) 9.5 (6.6–13.8) 9.6 (6.5–12.5) 8 (6.8–11.3) 10 (7–15)
NCCN Risk group
Low 2 (4) 13 (10) 17 (17) 484 (15)
Medium 36 (78) 104 (81) 75 (74) 2347 (73)
High 8 (17) 12 (9) 9 (9) 385 (12)
CHHiP treatment allocation
74 Gy/37 Fr 16 (35) 41 (32) 30 (29) 1065 (33)
60 Gy/20 Fr 15 (32.5) 45 (35) 35 (35) 1074 (33)
57 Gy/19 Fr 15 (32.5) 43 (33) 36 (36) 1077 (34)
Hormone therapy
None 1 (2) 3 (2) 4 (4) 90 (3)
Bicalutamide monotherapy 6 (13) 29 (23) 21 (21) 403 (13)
LHRH agonist 39 (85) 96 (74) 74 (73) 2700 (83)
Unknown 0 (0) 1 (1) 2 (2) 9 (<1)
Duration of hormone therapy
Median (IQR) in days 107 (94–161) 145 (112–178) 147 (121–161) 168 (133–196)
Diabetes
Yes 6 (13) 14 (11) 10 (10) 342 (11)
No 40 (87) 107 (83) 83 (82) NA
Unknown 8 (6) 8 (8) NA
Hypertension
Yes 20 (43) 53 (41) 33 (33) 1276 (40)
No 25 (54) 68 (53) 60 (59) NA
Unknown 1 (2) 8 (6) 8 (8) NA
NCCN: National Comprehensive Cancer Network.
Fig. 1. Trial profile (*endpoints assessable means those patients with DICOM data and complete endpoint data for evaluation). DICOM: Digital imaging and Communications
in medicine and is a standard for storing and transmitting medical images; F: fractions.
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Fig. 2. Boxplots illustrating the dose distribution for the calculated dose (Gy) of the penile bulb by IGRT group. IGRT: image guided radiotherapy; IGRT-R: IGRT with reduced
margins; IGRT-S: IGRT with standard margins.
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Fig. 3. Boxplots summarising the impact of penile bulb dosimetry on the defined toxicity endpoints using clinician (RMH) reported outcomes. Defined endpoints: RMH Grade
2 EP; 0 = no; 1 = yes. p values determined by Wilcoxon rank sum.
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ED is a critical health-related quality of life outcome in men
treated for prostate cancer and the potential structures implicated
in ED need to be determined. Previous data have suggested PB dose
is associated with radiotherapy-induced ED [3,26]. Modern radio-
therapy techniques enable dose sculpting, causing steep dose gra-
dients at the edge of the target volume (i.e. region of the PB) and
IGRT improves treatment accuracy which permits reduced radio-
therapy margins. The CHHiP IGRT trial provides a unique dataset
to determine effect of PB dose on erectile function.
We have demonstrated a relationship between reduced PTV
margins enabled by IGRT and PB dose and the relationship
between PB dose and ED using CRO and PRO. Dose constraints
for the PB have been derived which are generalisable and couldbe implemented in radiotherapy planning. A consistent mean dose
constraint of around 20 Gy equivalent dose in 2 Gy per fraction
(Biologically Effective Dose = 33.6 Gy using a/b = 3 Gy) was found.
When using the physical dose data for 2 Gy fractionation, a statis-
tically significant mean dose constraint of 24 Gy was calculated,
with a suggestion of a mean dose constraint of 22 Gy for 3 Gy frac-
tionation (Table E7). These constraints are similar to the PB mean
dose threshold of 20 Gy determined in a smaller cohort (n = 41)
treated with moderate hypofractionation (around 2.5 Gy/f) [12].
However, these thresholds are a significant reduction from the
mean dose limit of 50 Gy recommended in QUANTEC [3], and the
50 Gy limit to 90% of PB suggested in the MRC RT01 trial [26]. In
our dataset, less than 7% of patients had PB mean doses of
>50 Gy. The more favourable dose distributions in the present
patient cohort may have enabled identification of lower
Fig. 4. Atlases of complication incidence for RMH Grade 2 erectile potency at 2 years in (A) all patients with recorded erectile potency at 2 years and (B) patients treated with
IGRT (standard and reduced margins) with recorded erectile potency at 2 years. Dose (Gy) is the equivalent dose in 2 Gy/F using alpha/beta ratio of 3 Gy. The colour of the box
is determined by the fractional incidence of the endpoint, with the orange to red representing 70–100%. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Model Variables Regression
coefficient
95%CI 95%CIMultiplication value AUC
Hosmer-
Lemeshow
test
RMH EP Constant
Age
PB mean dose
-8.79
0.12
0.02
-12.93 to -4.23
0.053 to 0.17
-0.0007 to 0.035
-
Age in years
Dose in Gy
0.70 0.62-0.76 Chi square: 6.64
p=0.5757
(model does fit
the data well)
Fig. 5. (A) Chosen model variables, regression coefficient, multiplication values for the variables included in the model and metrics exploring the performance of the model.
(B) ROC curve obtained applying model for RMH Grade 2 EP and calibration plot for internal validation. The circles represent the Hosmer-Lemeshow groups, the solid line
represents the identity line.
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icant differences within the literature may include variation in
penile bulb definition and contouring, different fractionation
schedules and treatment techniques. In this study, we used a single
outlining clinician for hypotheses generating and validation
cohorts to remove inter-observer variability inherent in PB con-
touring, which has been shown to impact on DVH parameters
[19]. Fractionation schedules were protocol defined and IMRT
+/ IGRT was used in all cases. Our results are in accord with aninterim analysis of the DUE-01 study which found maximum PB
dose as a predictive factor for ED [21]. However, due to the small
PB volume and potential substantial impact inter-observer con-
touring variability has on dose-volume parameters [19], we sug-
gest that mean PB dose is likely to be a more robust metric for
use in radiotherapy planning.
ED post-radiotherapy is multifactorial and although PB dose is
associated with ED, it may be a surrogate for surrounding struc-
tures, such as neurovascular bundles and internal pudendal
J. Murray et al. / Clinical and Translational Radiation Oncology 21 (2020) 77–84 83arteries, which are not easily visualised on CT, but can be seen on
MRI [27]. Further studies using MR planning will enable interroga-
tion of these structures to determine associated dose volume rela-
tionships with ED. Although the PB is best identified on MRI, it is
visible on CT and, hence, a recognised structure of interest within
the RTOG contouring atlas [17]. The introduction of MRI-based
treatment planning and image guidance permits more accurate
identification of the prostate apex and PB during treatment plan-
ning and delivery, which may enable PB sparing. Additionally,
although planning target volume coverage should not be jeopar-
dised, the creation of PB as an objective function for prostate radio-
therapy optimisation should be considered. This goal appears
feasible as around 50% of patients within the whole cohort
achieved a PB mean dose < 20 Gy, approaching 80% for patients
within the IGRT-R group.
Radiotherapy dose constraints provide a practical means of
using dose–response relationships to inform radiotherapy plan-
ning in an evidence-based manner. A dose threshold constraint is
the best cut point in the data, being used as a proxy for the whole
dose-volume complication distribution. Further benefit may be
seen reducing the mean PB dose as far as possible, without com-
promising other aspects of the treatment plan.
Limitations of this study include that the sub-study was not
powered to compare the randomised groups and that there was
only a single time-point assessment of PRO. However, this is the
largest reported multicentre series of patients evaluating ED
post-radiotherapy using both CRO and PRO. Results have shown
significant and consistent association between PB dose and ED
independent of scoring system, strengthening validity of these
findings.
To our knowledge this predictive model for EBRT induced erec-
tile dysfunction is the first to include PB dose. The derived model
also included age, which is an established risk factor for ED after
treatment [28,29]. The discriminative power of the final multivari-
able model was good, with AUC = 0.70. External validation of the
model showed moderate discriminative power (AUC = 0.68), giving
a very favourable optimism factor with this model (0.02). However,
the similar radiotherapy treatment characteristics and inclusion/
exclusion criteria for both cohorts may partly explain this concor-
dance in model performance described. Further analyses with
additional datasets should be pursued.
ED is multifactorial and this study has explored limited clinical
factors, with patients who reported baseline impairment being
excluded from analysis. In addition, the median 12 month testos-
terone levels in those patients with reported RMH Grade 2 EP
was above the postulated threshold of 8 nmol/l, where the rela-
tionship between testosterone and sexual functioning is very low
[30]. Larger studies interrogating role of PB dose in post-
radiotherapy ED should be encouraged, with further refinement
and validation of clinical prediction models. The aim will be to
enable personalised discussion of the risks for radiation-related
ED and support clinical decision-making.
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